Monopar Therapeutics reported earnings of -$ 0.72 per MNPR share on Nov 12, 2026, beating analysts' expectations by
| Report Date | Nov 12, 2026 |
|---|---|
| Forecasted EPS | -$ 0.72 |
| Earnings Per Share (Surprise) | -$ 0.72 ($ 0.00) |
| Last Year's EPS | -$ 0.45 |
| EPS YoY Change |
Out of the last 43 earnings reporting periods, Monopar Therapeutics beat analysts’ expectations 16 times and fell short of expectations 12 time(s). Monopar Therapeutics reported earnings per share of -$ 0.72 in the last report falling to reach an estimated EPS of -$ 0.72 by
| Report Date | Forecasted EPS | Reported EPS | Last Year's EPS | EPS YoY Change |
|---|---|---|---|---|
| Nov 12, 2026 | -$ 0.72 | -$ 0.72 | -$ 0.48 | |
| Aug 12, 2026 | -$ 0.64 | -$ 0.62 | -$ 0.35 | |
| May 14, 2026 | -$ 1.06 | -$ 0.46 | -$ 0.38 | |
| Mar 27, 2026 | -$ 0.51 | -$ 0.61 | -$ 2.23 | |
| Nov 13, 2025 | -$ 0.46 | -$ 0.48 | -$ 0.37 | |
| Aug 12, 2025 | -$ 0.47 | -$ 0.35 | -$ 0.50 | |
| May 13, 2025 | -$ 0.65 | -$ 0.38 | -$ 0.50 | |
| Mar 31, 2025 | -$ 0.36 | -$ 2.23 | -$ 0.60 | |
| Nov 8, 2024 | -$ 0.46 | -$ 0.37 | -$ 0.70 | |
| Aug 9, 2024 | -$ 0.45 | -$ 0.50 | -$ 0.80 | |
| May 9, 2024 | -$ 0.85 | -$ 0.50 | -$ 0.95 | |
| Mar 28, 2024 | -$ 0.85 | -$ 0.60 | -$ 1.10 | |
| Nov 9, 2023 | -$ 0.95 | -$ 0.70 | -$ 0.95 | |
| Aug 10, 2023 | -$ 0.95 | -$ 0.80 | -$ 0.22 | |
| May 11, 2023 | -$ 1.00 | -$ 0.95 | -$ 0.95 | |
| Mar 23, 2023 | -$ 1.05 | -$ 1.10 | -$ 0.21 | |
| Nov 10, 2022 | -$ 1.15 | -$ 0.95 | -$ 1.00 | |
| Aug 11, 2022 | -$ 0.21 | -$ 0.22 | -$ 0.85 | |
| May 12, 2022 | -$ 1.20 | -$ 0.95 | -$ 0.80 | |
| Mar 24, 2022 | -$ 0.19 | -$ 0.21 | -$ 0.95 |
Monopar Therapeutics’s stock was trading at $ 71.73 on Nov 11, 2026 a day before the last earnings report was released.Following the release of the earnings report, MNPR’s price increased to $ 72.00 on Nov 13, 2026, recording a
| Report Date | EPS | Price 1 Day Before | Price 1 Day After | Change |
|---|---|---|---|---|
| Nov 12, 2026 | -$ 0.72 | $ 71.73 | $ 72.00 | |
| Aug 12, 2026 | -$ 0.62 | $ 114.46 | $ 110.41 | |
| May 14, 2026 | -$ 0.46 | $ 61.44 | $ 59.27 | |
| Mar 27, 2026 | -$ 0.61 | $ 54.56 | $ 53.29 | |
| Nov 13, 2025 | -$ 0.48 | $ 82.58 | $ 78.00 | |
| Aug 12, 2025 | -$ 0.35 | $ 31.34 | $ 33.51 | |
| May 13, 2025 | -$ 0.38 | $ 35.10 | $ 37.11 | |
| Mar 31, 2025 | -$ 2.23 | $ 40.33 | $ 33.43 | |
| Nov 8, 2024 | -$ 0.37 | $ 15.73 | $ 16.66 | |
| Aug 9, 2024 | -$ 0.50 | $ 2.75 | $ 2.36 | |
| May 9, 2024 | -$ 0.50 | $ 3.75 | $ 3.36 | |
| Mar 28, 2024 | -$ 0.60 | $ 3.69 | $ 3.40 | |
| Nov 9, 2023 | -$ 0.70 | $ 2.15 | $ 1.84 | |
| Aug 10, 2023 | -$ 0.80 | $ 3.63 | $ 3.55 | |
| May 11, 2023 | -$ 0.95 | $ 5.00 | $ 4.68 | |
| Mar 23, 2023 | -$ 1.10 | $ 13.65 | $ 14.50 | |
| Nov 10, 2022 | -$ 0.95 | $ 21.95 | $ 14.15 | |
| Aug 11, 2022 | -$ 0.22 | $ 9.13 | $ 9.75 | |
| May 12, 2022 | -$ 0.95 | $ 10.05 | $ 10.10 | |
| Mar 24, 2022 | -$ 0.21 | $ 13.30 | $ 12.55 |
Monopar Therapeutics released its most recent earnings reports in November 2026, August 2026, May 2026, March 2026 respectively. Generally, most companies have a consistent schedule for their earnings releases. However, companies do not necessarily release their earnings reports at the same time each year. The timing of earnings releases can vary depending on a company's fiscal year, industry norms, and internal reporting practices.
Monopar Therapeutics missed analysts’ expectations during the last earnings period by
